{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=14", "query": { "intervention": "Arm 1- Dose Expansion", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 464, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Expansion&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:36:05.200Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06663319", "title": "A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms", "Gastrointestinal Neoplasms" ], "interventions": [ { "name": "JNJ-89402638", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2024-10-15", "completion_date": "2028-07-19", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 6, "location_summary": "Tucson, Arizona • Aurora, Colorado • Sarasota, Florida + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06663319" }, { "nct_id": "NCT06939283", "title": "A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "WTX-330", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Werewolf Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2025-04-21", "completion_date": "2026-04-23", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06939283" }, { "nct_id": "NCT03850574", "title": "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute", "Refractory AML", "Relapsed Adult AML", "Myelodysplastic Syndrome With Excess Blasts-2", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "Tuspetinib", "type": "DRUG" }, { "name": "Venetoclax Oral Tablet", "type": "DRUG" }, { "name": "Azacitidine for Intravenous Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aptose Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2019-03-11", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Duarte, California • Irvine, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03850574" }, { "nct_id": "NCT02948426", "title": "Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Autologous Monocytes + ACTIMMUNE + SYLATRON", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2017-02-08", "completion_date": "2020-09-29", "has_results": true, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02948426" }, { "nct_id": "NCT03177291", "title": "Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Non Small Cell Lung Cancer", "Advanced Cancer", "Metastatic Lung Cancer", "Squamous Cell Lung Cancer", "Non-Squamous Non-Small Cell Neoplasm of Lung" ], "interventions": [ { "name": "Pirfenidone", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2017-09-26", "completion_date": "2024-12-04", "has_results": false, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03177291" }, { "nct_id": "NCT04895748", "title": "DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "DFF332", "type": "DRUG" }, { "name": "RAD001", "type": "DRUG" }, { "name": "PDR001", "type": "DRUG" }, { "name": "NIR178", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 40, "start_date": "2021-11-30", "completion_date": "2026-02-13", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 5, "location_summary": "Duarte, California • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895748" }, { "nct_id": "NCT04303117", "title": "PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Kaposi Sarcoma" ], "interventions": [ { "name": "PDS01ADC", "type": "DRUG" }, { "name": "M7824", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 80, "start_date": "2020-07-13", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04303117" }, { "nct_id": "NCT05935748", "title": "Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "ccRCC", "Clear Cell Renal Cell Carcinoma", "Kidney Cancer", "Kidney Neoplasms", "Renal Cancer", "Renal Neoplasms", "Recurrent Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Refractory Renal Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Carcinoma", "Neoplasms", "Carcinoma, Renal Cell", "Neoplasms, Glandular and Epithelial", "Neoplasm by Histology", "Adenocarcinoma", "Urologic Neoplasms", "Urogenital Neoplasms", "Neoplasms by Site", "Kidney Diseases", "Urologic Diseases" ], "interventions": [ { "name": "NKT2152", "type": "DRUG" }, { "name": "palbociclib", "type": "DRUG" }, { "name": "sasanlimab", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NiKang Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2023-07-28", "completion_date": "2025-09-04", "has_results": true, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 8, "location_summary": "La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05935748" }, { "nct_id": "NCT05867121", "title": "A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RO7496353", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2023-10-02", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 3, "location_summary": "Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867121" }, { "nct_id": "NCT06840886", "title": "A Study of PHST001 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Ovarian Cancer", "Endometrial Cancer", "Cholangiocarcinoma", "CNS Tumor", "Breast Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Carcinosarcoma, Ovarian" ], "interventions": [ { "name": "PHST001", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Mirvetuximab Soravtansine", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pheast Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 426, "start_date": "2025-03-31", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-15T12:36:05.200Z", "location_count": 20, "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06840886" } ] }